等待開盤 09-23 09:30:00 美东时间
+0.425
+4.70%
https://www.marijuanamoment.net/massachusetts-lawmakers-approve-bill-to-create-psychedelic-therapy-pilot-program/
09-13 00:30
Mind Medicine ( ($MNMD) ) just unveiled an update. MindMed has announced its pa...
09-10 04:03
Mind Medicine ( ($MNMD) ) has provided an update. MindMed announced the issuanc...
09-10 03:35
Mind Medicine ( ($MNMD) ) has shared an announcement. On September 4, 2025, Min...
09-04 23:47
The Phase 2b study demonstrated a statistically significant dose-response relationship at the primary endpoint following a single administration of MM120 across four dose levels, with improvements sustained throughout
09-04 23:07
https://www.marijuanamoment.net/u-s-senate-committee-to-hold-hearing-on-benefits-of-psychedelics-for-military-veterans/
08-22 02:35
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• **财务业绩**: Mind Medicine (MindMed) 截至2025年6月30日的第二季度财务数据显示,公司持有的现金、现金等价物和投资总额为2.379亿美元。2025年研究与开发(R&D)费用为2980万美元,相较于2024年的1460万美元增加了1520万美元。2025年第二季度的管理与行政(G&A)费用为1110万美元,相较于2024年的980万美元增加了130万美元。</p> <p>• **财务指标变化**: - **现金与投资**:截至2025年6月30日,公司现金、现金等价物和投资总额为2.379亿美元,预
08-12 12:05
Chardan Capital analyst Rudy Li maintains Mind Medicine (NASDAQ:MNMD) with a Buy and maintains $20 price target.
08-01 19:36
Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (...
07-31 16:32
据知情人士透露,艾伯维正在洽谈收购专注于精神健康治疗的Gilgamesh Pharmaceuticals。如果交易成功,将增强艾伯维在精神疾病治疗方面的产品管线。
07-31 08:52